Cart
sales@molnova.com
Nimotuzumab
CAS No. 828933-51-3
Nimotuzumab( —— )
Catalog No. M28966 CAS No. 828933-51-3
Nimotuzumab is a humanized therapeutic monoclonal antibody against epidermal growth factor receptor EGFR).
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 1017 | In Stock |
|
| 10MG | 1359 | In Stock |
|
| 25MG | 2024 | In Stock |
|
| 50MG | 2688 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameNimotuzumab
-
NoteResearch use only, not for human use.
-
Brief DescriptionNimotuzumab is a humanized therapeutic monoclonal antibody against epidermal growth factor receptor EGFR).
-
DescriptionNimotuzumab is a humanized therapeutic monoclonal antibody against epidermal growth factor receptor EGFR).
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayAngiogenesis
-
TargetEGFR
-
Recptor——
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number828933-51-3
-
Formula Weight——
-
Molecular Formula——
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Chen JB, et al. Design and synthesis of novel dual-action compounds targeting the adenosine A(2A) receptor and adenosine transporter for neuroprotection. ChemMedChem. 2011 Aug 1;6(8):1390-1400.
molnova catalog
related products
-
AG-825
AG-825（Tyrphostin C15） is a selective and competitive ErbB2 inhibitor that inhibits tyrosine phosphorylation with an IC50 value of 0.35 μM.AG-825 (Tyrphostin C15) inhibits HER2 and shows anticancer activity in a mouse xenograft model of breast cancer.
-
R162
R162 is an effective glutamate dehydrogenase 1 (GDH1) inhibitor.
-
EGFR-IN-1 hydrochlor...
EGFR-IN-1 hydrochloride is an irreversible and specific inhibitor of L858R/T790M mutant EGFR, with 100-fold selectivity over wild-type EGFR.
